Job Title
Assistant Professor in Health Economics
Department
WMS - Health Sciences
Email
- 'Auguste, Peter E., 'Mistry, Hema, 'McCarthy, Noel D., 'Sutcliffe, Paul, 'Clarke, Aileen, 2022. 'Cost-effectiveness of testing for latent tuberculosis infection in people with HIV. AIDS, 36 (1), pp. 1-9
- 'Connock, Martin, 'Auguste, Peter, 'Armoiry, Xavier, 2021. 'A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme. The European Journal of Health Economics, 22 (1), pp. 89-100
- Connock, Martin, Andronis, Lazaros, Auguste, Peter, Dussart, Claude, Armoiry, Xavier, 2020. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ?value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opinion on Biological Therapy, 20 (7), pp. 823-827
- Connock, Martin, Auguste, Peter, Dussart, Claude, Guyotat, Jacques, Armoiry, Xavier, 2019. Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma : an updated evaluation using a partitioned survival model. Journal of Neuro-Oncology, pp. 1-7
- Gallacher, Daniel C., Auguste, Peter, Connock, Martin, 2019. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017. International Journal of Technology Assessment in Health Care, 35 (02), pp. 160-167
- Gallacher, Daniel C., Auguste, Peter, Connock, M., 2019. How do pharmaceutical companies model survival of cancer patients? A review of NICE Single Technology Appraisals in 2017. International Journal of Technology Assessment in Health Care, 35 (2), pp. 160-167
- Gallacher, Daniel C., Auguste, Peter, Royle, Pamela, Mistry, Hema, Armoiry, Xavier, 2019. A systematic review of economic evaluations assessing the cost-effectiveness of licensed drugs used for previously treated epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced/metastatic non-small cell lung cancer. Clinical Drug Investigation, 39, pp. 1153-1174
- Gallacher, Daniel C., Armoiry, Xavier, Auguste, Peter, Court, Rachel A., Mantopoulos, Theodoros, Patterson, Jacoby, De Santis, Maria, Cresswell, Joanne, Mistry, Hema, 2019. Pembrolizumab for previously treated advanced or metastatic urothelial cancer : an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 37, pp. 19-27
- Melendez-Torres, G. J., Armoiry, Xavier, Court, Rachel A., Patterson, Jacoby, Kan, Alan, Auguste, Peter, Madan, Jason, Counsell, Carl, Ciccarelli, Olga, Clarke, Aileen, 2018. Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis : systematic review and network meta-analysis of trials including recommended dosages. BMC Neurology, 18 (1)
- Armoiry, Xavier, Kanda, Akira, Melendez-Torres, G. J., Court, Rachel A., Sutcliffe, P. (Paul), Auguste, Peter, Madan, Jason, Counsell, C., Clarke, Aileen, 2018. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome : a systematic review of randomised controlled trials and network meta-analysis. Journal of Neurology, 265 (5), pp. 999-1009
- Mistry, Hema, Auguste, Peter, Lois, Noemi, Waugh, Norman, 2017. Diabetic retinopathy and the use of laser photocoagulation : is it cost-effective to treat early?. BMJ Open Ophthalmology, 2 (1)
- Auguste, Peter, Tsertsvadze, Alexander, Pink, Joshua, Court, Rachel A., McCarthy, Noel D., Sutcliffe, P. (Paul), Clarke, Aileen, 2017. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis : systematic review and meta-analysis. BMC Infectious Diseases, 17 (1)
- Freeman, Karoline, Taylor-Phillips, Sian, Connock, M., Court, Rachel A., Tsertsvadze, Alexander, Shyangdan, D. (Deepson), Auguste, Peter, Mistry, Hema, Arasaradnam, Ramesh P., Sutcliffe, P. (Paul), Clarke, Aileen, 2017. Test accuracy of drug and antibody assays for predicting response to anti-Tumour Necrosis Factor treatment in Crohn?s disease : a systematic review and meta-analysis. BMJ Open, 7
- Melendez-Torres, G. J., Auguste, Peter, Armoiry, Xavier, Maheswaran, H., Court, Rachel A., Madan, Jason, Kan, A., Lin, S., Counsell, C., Patterson, J., Rodrigus, J., Ciccarelli, O., Fraser, Hannah, Clarke, Aileen, 2017. Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation. Health Technology Assessment, 21 (52)
- Melendez-Torres, GJ, Auguste, Peter, Armoiry, Xavier, Maheswaran, Hendramoorthy, Court, Rachel A., Madan, Jason, Kan, Alan, Lin, Stephanie, Counsell, Carl, Patterson, Jacoby, Rodrigues, Jeremy, Ciccarelli, Olga, Fraser, Hannah, Clarke, Aileen, 2017. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment, 21 (52), pp. 1-352
- Freeman, Karoline, Connock, M., Auguste, Peter, Taylor-Phillips, Sian, Mistry, Hema, Shyangdan, D. (Deepson), Court, Rachel A., Arasaradnam, Ramesh P., Sutcliffe, P. (Paul), Clarke, Aileen, 2016. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-?) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-?-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn?s disease: systematic reviews and economic modelling. Health Technology Assessment, 20 (83), pp. 1-288
- Auguste, Peter, Tsertsvadze, Alexander, Pink, Joshua, Court, Rachel A., Seedat, Farah, Gurung, Tara, Freeman, Karoline, Taylor-Phillips, Sian, Walker, Clare, Madan, Jason, Kandala, Ngianga-Bakwin, Clarke, Aileen, Sutcliffe, P. (Paul), 2016. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis : systematic review and economic evaluation. Health Technology Assessment, 20 (38), pp. 1-678
- Auguste, Peter, Tsertsvadze, Alexander, Court, Rachel A., Pink, Joshua, 2016. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups. Tuberculosis, 99, pp. 81-91
- Royle, Pamela, Mistry, Hema, Auguste, Peter, Shyangdan, D., Freeman, Karoline, Lois, Noemi, Waugh, Norman, 2015. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy : systematic review and economic evaluation. Health Technology Assessment, 19 (51), pp. 1-248
- Auguste, Peter, Barton, P., Meads, C., Davenport, C., Malysiak, S., Kowalska, Marta, Zapalska, A., Guest, P., Martin-Hirsch, P. L., Borowiack, E., Khan, K., Sundar, Santhanam, Roberts, T., 2014. Evaluating PET?CT in routine surveillance and follow-up after treatment for cervical cancer : a cost-effectiveness analysis. BJOG : An International Journal of Obstetrics & Gynaecology, 121 (4), pp. 464-476
- Meads, C., Davenport, C., Malysiak, S., Kowalska, Marta, Zapalska, A., Guest, P., Martin-Hirsch, P. L., Borowiack, E., Auguste, Peter, Barton, P., Roberts, T. P., Khan, K., Sundar, Santhanam, 2014. Evaluating PET-CT in the detection and management of recurrent cervical cancer : systematic reviews of diagnostic accuracy and subjective elicitation. BJOG: An International Journal of Obstetrics & Gynaecology, 121 (4), pp. 398-407
- Mistry, Hema, Auguste, Peter, Lois, Noemi, Waugh, Norman, 2014. Non-proliferative diabetic retinopathy : is it cost-effective to treat early?. Value in Health, 17 (7)
- Althaus, Christian L., Turner, Katherine M. E., Mercer, Catherine H., Auguste, Peter, Roberts, Tracy E., Bell, Gill, Herzog, Sereina A., Cassell, Jackie A., Edmunds, W. John, White, Peter J., Ward, Helen, Low, Nicola, 2014. Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections : observational study, systematic reviews and mathematical modelling. Health Technology Assessment, 18 (2)
- Jackson, Louise J., Auguste, Peter, Lowen, Nicola, Roberts, Tracy E., 2014. Valuing the health states associated with Chlamydia trachomatis infections and their sequelae : a systematic review of economic evaluations and primary studies. Value in Health, 17 (1), pp. 116-130
- Green, Colin, Auguste, Peter, Lloyd, J. L., Wyatt, K. M., 2012. Modelling future outcomes to estimate the cost-effectiveness of interventions related to childhood/adolescent overweight/obesity. The Lancet, 380
- Ewer, A. K., Furmston, A. T., Middleton, L. J., Deeks, J. J., Daniels, J. P., Pattison, H. M., Powell, R., Roberts, T. E., Barton, P., Auguste, Peter, Bhoyar, A., Thangaratinam, S. (Shakila), Tonks, A. M., Satodia, P., Deshpande, S., Kumararatne, B., Sivakumar, S., Mupanemunda, R., Khan, K. S., 2012. Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness. Health Technology Assessment, 16 (2)
- Roberts, T. E., Barton, P. M., Auguste, Peter, Middleton, L. J., Furmston, A. T., Ewer, A. K., 2012. Pulse oximetry as a screening test for congenital heart defects in newborn infants : a cost-effectiveness analysis. Archives of Disease in Childhood, 97 (3), pp. 221-226
- Auguste, Peter, Barton, P., Hyde, C., Roberts, T. E., 2011. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment, 15 (18)
- Armoiry, Xavier, Auguste, Peter, Clarke, Aileen, 2018. Beta interferons and glatiramer acetate for treating multiple sclerosis. National Institute for Health and Care Excellence
| Title | Funder | Award start | Award end |
|---|---|---|---|
| NIHR Evidence Synthesis Group stage 2 | National Institute for Health Research (NIHR DoH) | 01 Apr 2023 | 31 Mar 2028 |
| TAR 3 - Production of Technology Assessment Reviews (TAR) | National Institute for Health Research (NIHR DoH) | 01 Apr 2022 | 31 Mar 2027 |
| CyteCount: a novel bacterial electrophysiology method for rapid phenotypic antibiotic susceptibility testing of bacteria detected in clinical blood cultures Full stage | National Institute for Health Research (NIHR DoH) | 01 Jan 2024 | 31 Dec 2026 |
| Case finding of obstructive sleep apnoea in primary care using a novel device a randomised controlled trial: FOUND (Finding OSA Using a Novel Device) | National Institute for Health Research (NIHR DoH) | 01 Nov 2022 | 30 Apr 2025 |
| NIHR HTA Stage 2 (stage 1 on ideate 74591) : Ventilation technologies: an overview of systematic reviews and meta-analyses | National Institute for Health Research (NIHR DoH) | 01 Sep 2023 | 28 Feb 2025 |
| NIHR HTA Stage 2: Medication support interventions for people with learning disability | National Institute for Health Research (NIHR DoH) | 01 Sep 2022 | 30 Jun 2024 |
| NIHR TAR2 12 month extension and supplement - orginal award on IDEATE number 00169 under Aileen Clarke | National Institute for Health Research (DoH) | 01 Apr 2021 | 31 Mar 2022 |
| PHE Framework application: Cost-effectiveness of newborn blood spot screening for Tyrosinaemia type 1 using tandem mass spectrometry - an extension | Public Health England | 08 Jan 2021 | 31 Jul 2021 |